Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Latest news
Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge...
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward buil...
“Other companies come to us and want CDMO work in the biosimilar space because we know what we’re doing, but our goal...
Gdansk, Poland and Utrecht, The Netherlands 13th July 2020. In 2016, Polpharma Biologics acquired Dutch based Biocero...
We have developed our SPOT™ technology alongside our proprietary CHO cell line to increase the cell line specific pro...
The current situation caused by COVID-19 concerns us all. We had decided to help because we care. That’s why we have...
Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros C...
First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.
Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medicat...
Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a nat...
